title: Ocriplasmin for treatment of stage 2 macular holes: early clinical results.
abstract: OBJECTIVE
  To review clinical and structural outcomes of ocriplasmin for treatment of stage 2 macular holes.
  
  
  METHODS
  A retrospective review of the first patients with stage 2 macular holes to be treated with ocriplasmin at Massachusetts Eye and Ear Infirmary. All patients were imaged with spectral-domain optical coherence tomography (SD-OCT).
  
  
  RESULTS
  Eight patients with stage 2 macular holes received a single injection of 125 μg of ocriplasmin. One patient (12.5%) demonstrated macular hole closure. The posterior hyaloid separated from the macula in six eyes (75%). All seven holes that remained open showed enlargement in hole diameters (narrowest, apical, and basal) at 1 week and 1 month. All seven were successfully closed with surgery. Ellipsoid zone disruptions were observed by OCT in four eyes (50%) and persisted throughout follow-up (more than 6 months on average).
  
  
  CONCLUSIONS
  In early clinical results, the authors found a lower macular hole closure rate with ocriplasmin than previously reported. Enlargement was observed in all holes that failed to close with ocriplasmin. The authors found ellipsoid zone disruptions that persisted through 6 months of follow-up after ocriplasmin injection. Further work is needed to investigate the cause for these ellipsoid zone changes.
authors.forename: John B
authors.initials: JB
authors.lastname: Miller
authors.forename: Leo A
authors.initials: LA
authors.lastname: Kim
authors.forename: David M
authors.initials: DM
authors.lastname: Wu
authors.forename: Demetrios G
authors.initials: DG
authors.lastname: Vavvas
authors.forename: Dean
authors.initials: D
authors.lastname: Eliott
authors.forename: Deeba
authors.initials: D
authors.lastname: Husain
mesh_terms: D000368:Aged; D005260:Female; D005341:Fibrinolysin / Q000627:therapeutic use*; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D010446:Peptide Fragments / Q000627:therapeutic use*; D012167:Retinal Perforations / Q000188:drug therapy*; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence; D014792:Visual Acuity
chemical_list: D005343:Fibrinolytic Agents; D010446:Peptide Fragments; C054561:microplasmin; D005341:Fibrinolysin